65. 原発性免疫不全症候群 Primary immunodeficiency Clinical trials / Disease details


臨床試験数 : 500 薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04371939
(ClinicalTrials.gov)
November 5, 201929/4/2020Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich SyndromeRandomized, Two-arm Single-center Phase II Clinical Trial Comparing the Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich SyndromeWiskott-Aldrich SyndromeDrug: Romiplostim;Drug: EltrombopagFederal Research Institute of Pediatric Hematology, Oncology and ImmunologyNULLRecruitingN/A18 YearsAll30Phase 2Russian Federation
2NCT00909363
(ClinicalTrials.gov)
June 200927/5/2009Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) PatientsEffects Of Eltrombopag On Thrombocytopenia, Platelet Function and Bleeding In Patients With Wiskott-Aldrich Syndrome/X-Linked Thrombocytopenia.Wiskott-Aldrich Syndrome;Thrombocytopenia;BleedingDrug: Promacta;Diagnostic Test: blood drawing in patients with WAS;Diagnostic Test: blood drawing in healthy controlsWeill Medical College of Cornell UniversityNovartis PharmaceuticalsTerminated3 Months80 YearsMale24Phase 2United States